AbCellera Investor Conference Presentation Deck
JPM HEALTHCARE CONFERENCE 2024
COPYRIGHT © ABCELLERA
10
OUR ENGINE: T-CELL ENGAGER PLATFORM
Continued progress and differentiation for T-cell engager platform.
T-cell engagers have tremendous potential for the treatment of cancer and autoimmune
conditions but are technically challenging to design and engineer.
AbCellera's T-cell engager platform combines unique discovery capabilities, bispecific
engineering, and a panel of hundreds of diverse CD3-binding antibodies to potentially:
Improve the safety profile
of T-cell engagers
by creating bispecific antibodies that
achieve potent tumor killing with
reduced cytokine release, which can
help address dose-limiting toxicity.
Expand the accessible
target space for T-cell
engagers in solid tumors
by enabling discovery of antibodies
that are highly specific to
MHC-peptide complexes.View entire presentation